UK indefinitely bans puberty blockers for teenagers due to “unacceptable risk”
Puberty blockers for people aged under 18 years with gender dysphoria will be indefinitely banned by the UK Government following…
12 Dec 2024
Meitheal gains US commercial rights for CABP treatment therapy
Meitheal Pharmaceuticals has gained exclusive US commercial rights for a first-in-class semi-synthetic pleuromutilin antibiotic, XENLETA (lefamulin acetate), to treat community-acquired bacterial pneumonia (CABP) in the adult population. The rights were…
12 Dec 2024
Sanofi’s combo vaccines gain FDA fast track designation
Sanofi has announced that its two combination vaccine candidates, designed to prevent both influenza and Covid-19 infections in people aged 50 years and above, have received fast track designation from…
11 Dec 2024
Vifor Pharma offers £23m to NHS to resolve CMA investigation
The UK’s Competition and Markets Authority (CMA) has received a £23m ($29m) offer from Vifor Pharma for the NHS to address competition concerns that the regulator has been investigating. Part…
11 Dec 2024
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia
Er-Kim has extended its exclusive agreement with Ascendis Pharma, broadening the reach of three endocrinology treatments across multiple countries in Eurasia. This follows the initial exclusive distribution arrangement announced in…
11 Dec 2024
Relation-GSK to drive fibrotic and osteoarthritis developments
Relation has announced two strategic collaborations with GSK, focusing on the discovery and validation of therapeutics that target fibrotic diseases and osteoarthritis. Relation will obtain a $45m upfront payment from…
11 Dec 2024
Better prevention and treatment options needed for genital herpes, WHO says
A World Health Organization (WHO) director has called for “better prevention and treatment options” after the agency released new estimates of genital herpes prevalence. Dr Meg Doherty, director of global…